Oncolytic virotherapy combines direct tumor cell lysis with immune activation to generate antitumor T-cell responses. We report results from a phase I trial of intravenous (IV) vesicular stomatitis virus expressing human interferon-β and the sodium iodide symporter (VSV-hIFNβ-NIS) in patients with stage IV or recurrent endometrial cancer (EC).Patients with stage IV or recurrent EC (largest tumor ≤5 cm) received a single IV infusion of VSV-hIFNβ-NIS in a 3+3 dose-escalation trial. Five dose levels (5×10⁹–3.5×10¹¹ TCID₅₀) were planned. The primary endpoint was maximum tolerated dose (MTD). Secondary endpoints included pharmacokinetics, pharmacodynamics, RECIST v1.1 response, and exploratory immune correlates. Tumor assessment was performed on day 29. A post hoc analysis evaluated durable clinical benefit after VSV-hIFNβ-NIS and subsequent immune checkpoint inhibitor (ICI)-based therapy.Twenty-one eligible patients were treated. No dose-limiting toxicities (DLTs) occurred at dose level (DL)1. One grade 3 dehydration event associated with cytokine release syndrome at DL2 prompted revision of the DLT definition; no additional DLTs occurred at DL2 or DL3. One of six patients at DL4 experienced grade 3 delirium meeting DLT criteria. Escalation to DL5 was not feasible because of investigational product volume limitations; therefore, the MTD was not reached. Median age was 65 years, with a median of two prior treatment lines. Treatment-related adverse events were transient hematologic toxicities, liver enzyme elevations, and cytokine release syndrome. Two patients achieved stable disease ≥6 months after VSV-hIFNβ-NIS. Among 15 patients subsequently treated with ICI-containing regimens, four achieved durable stable disease; median overall survival was 20.2 months. Intravenous VSV-hIFNβ-NIS demonstrated an acceptable safety profile, and the MTD was not reached. Durable disease stabilization following subsequent ICI therapy, supports further evaluation of VSV-hIFNβ-NIS
21 June 2026 in Journal of Minimally Invasive Gynecology